A necessary cut at Novo Nordisk

The criticism of the current supervisory board appears plausible. Novo Nordisk has made significant mistakes in its most important market, the USA: The demand for Wegovy was massively underestimated, and production capacities were expanded too late – resulting in the emergence of legal copycat products that lost market share. More US expertise in the management team would likely benefit the company. At the same time, it should be acknowledged that the Danes have set benchmarks in research and development for decades. Their strength lies in science...